Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 426

1.

COMPETITIVE TESTING THE WHO 2010 VS THE WHO 2017 GRADING OF PANCREAS NEUROENDOCRINE NEOPLASIA: DATA FROM A LARGE INTERNATIONAL COHORT STUDY.

Rindi G, Klersy C, Albarello L, Baudin E, Bianchi A, Büchler MW, Caplin M, Couvelard A, Cros J, de Herder WW, Delle Fave G, Doglioni C, Federspiel B, Fischer L, Fusai G, Gavazzi F, Hansen C, Inzani F, Jann H, Komminoth P, Knigge U, Landoni L, La Rosa S, Lawlor R, Luong T, Marinoni I, Panzuto F, Pape UF, Partelli S, Perren A, Rinzivillo M, Rubini C, Ruszniewski P, Scarpa A, Schmitt AM, Schinzari G, Scoazec JY, Sessa F, Solcia E, Spaggiari P, Toumpanakis C, Vanoli A, Wiedenmann B, Zamboni G, Zandee W, Zerbi A, Falconi M.

Neuroendocrinology. 2018 Oct 9. doi: 10.1159/000494355. [Epub ahead of print]

PMID:
30300897
2.

Predicting the efficacy of surgery for pain relief in patients with alcoholic chronic pancreatitis.

Bordaçahar B, Couvelard A, Vullierme MP, Bucchini L, Sauvanet A, Dokmak S, Ruszniewski P, Lévy P, Rebours V.

Surgery. 2018 Nov;164(5):1064-1070. doi: 10.1016/j.surg.2018.05.025. Epub 2018 Jul 18.

PMID:
30029988
3.

Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process.

Faille D, Bourrienne MC, de Raucourt E, de Chaisemartin L, Granger V, Lacroix R, Panicot-Dubois L, Hammel P, Lévy P, Ruszniewski P, Ajzenberg N, Rebours V.

Oncotarget. 2018 May 29;9(41):26453-26465. doi: 10.18632/oncotarget.25458. eCollection 2018 May 29.

4.

Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E; NETTER-1 Study Group.

J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.

PMID:
29878866
5.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

Aparicio T, Ducreux M, Faroux R, Barbier E, Manfredi S, Lecomte T, Etienne PL, Bedenne L, Bennouna J, Phelip JM, François E, Michel P, Legoux JL, Gasmi M, Breysacher G, Rougier P, De Gramont A, Lepage C, Bouché O, Seitz JF; for FFCD investigators.

Eur J Cancer. 2018 Jul;98:1-9. doi: 10.1016/j.ejca.2018.03.031. Epub 2018 May 26.

6.

Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study.

Sibeoni J, Khannoussi W, Manolios E, Rebours V, Revah-Levy A, Ruszniewski P.

Oncotarget. 2018 Jan 31;9(18):14138-14147. doi: 10.18632/oncotarget.24347. eCollection 2018 Mar 6.

7.

Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.

Pellat A, Dreyer C, Couffignal C, Walter T, Lombard-Bohas C, Niccoli P, Seitz JF, Hentic O, André T, Coriat R, Faivre S, Zappa M, Ruszniewski P, Pote N, Couvelard A, Raymond E.

Neuroendocrinology. 2018;107(1):24-31. doi: 10.1159/000487237. Epub 2018 Mar 8.

PMID:
29518779
8.

In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma.

Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T.

Oncotarget. 2018 Jan 9;9(6):6952-6967. doi: 10.18632/oncotarget.24084. eCollection 2018 Jan 23.

9.

Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos).

Palazzo M, Napoléon B, Gincul R, Pioche M, Pujol B, Lefort C, Fumex F, Hautefeuille V, Fabre M, Cros J, Felce M, Couvelard A, Sauvanet A, Lévy P, Ruszniewski P, Palazzo L.

Gastrointest Endosc. 2018 Jun;87(6):1481-1488. doi: 10.1016/j.gie.2017.12.033. Epub 2018 Jan 8.

PMID:
29325706
10.

Prognosis of sporadic resected small (≤2 cm) nonfunctional pancreatic neuroendocrine tumors - a multi-institutional study.

Sallinen VJ, Le Large TYS, Tieftrunk E, Galeev S, Kovalenko Z, Haugvik SP, Antila A, Franklin O, Martinez-Moneo E, Robinson SM, Panzuto F, Regenet N, Muffatti F, Partelli S, Wiese D, Ruszniewski P, Dousset B, Edwin B, Bartsch DK, Sauvanet A, Falconi M, Ceyhan GO, Gaujoux S; Pancreas 2000 research group.

HPB (Oxford). 2018 Mar;20(3):251-259. doi: 10.1016/j.hpb.2017.08.034. Epub 2017 Oct 5.

11.

Liver transarterial embolizations in metastatic neuroendocrine tumors.

de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P.

Rev Endocr Metab Disord. 2017 Dec;18(4):459-471. doi: 10.1007/s11154-017-9431-2. Review.

PMID:
28975561
12.

Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.

Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J.

Expert Opin Drug Saf. 2017 Dec;16(12):1413-1426. doi: 10.1080/14740338.2017.1380624. Epub 2017 Sep 28. Review.

PMID:
28920492
13.

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.

Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A.

Neuroendocrinology. 2018;106(3):274-282. doi: 10.1159/000480239. Epub 2017 Aug 11.

PMID:
28803235
14.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.

de Mestier L, Cros J, Neuzillet C, Hentic O, Egal A, Muller N, Bouché O, Cadiot G, Ruszniewski P, Couvelard A, Hammel P.

Neuroendocrinology. 2017;105(4):412-425. doi: 10.1159/000475527. Epub 2017 Aug 12. Review.

15.

Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases.

Lorenzo D, Maire F, Stefanescu C, Gornet JM, Seksik P, Serrero M, Bournet B, Marteau P, Amiot A, Laharie D, Trang C, Coffin B, Bellaiche G, Cadiot G, Reenaers C, Racine A, Viennot S, Pauwels A, Bouguen G, Savoye G, Pelletier AL, Pineton de Chambrun G, Lahmek P, Nahon S, Abitbol V; GETAID-AIP study group.

Clin Gastroenterol Hepatol. 2018 Jan;16(1):59-67. doi: 10.1016/j.cgh.2017.07.033. Epub 2017 Aug 4.

PMID:
28782667
16.

Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours.

Neuzillet C, de Mestier L, Rousseau B, Mir O, Hebbar M, Kocher HM, Ruszniewski P, Tournigand C.

Pharmacol Ther. 2018 Jan;181:49-75. doi: 10.1016/j.pharmthera.2017.07.006. Epub 2017 Jul 16. Review.

PMID:
28723416
17.

Management of gastric neuro-endocrine tumours in a large French national cohort (GTE).

Manfredi S, Walter T, Baudin E, Coriat R, Ruszniewski P, Lecomte T, Laurenty AP, Goichot B, Rohmer V, Roquin G, Cojocarasu OZ, Lombard-Bohas C, Lepage C, Morcet J, Cadiot G.

Endocrine. 2017 Sep;57(3):504-511. doi: 10.1007/s12020-017-1355-9. Epub 2017 Jun 29.

18.

Estimation of the prevalence of intraductal papillary mucinous neoplasm of the pancreas in the French population through patients waiting for liver transplantation.

Laurent L, Vullierme MP, Rebours V, Maire F, Hentic O, Francoz C, Durand F, Ruszniewski P, Lévy P.

United European Gastroenterol J. 2017 Jun;5(4):499-503. doi: 10.1177/2050640616664842. Epub 2016 Aug 16.

19.

Epidemiology of pancreatic cancer in France: descriptive study from the French national hospital database.

Maire F, Cibot JO, Compagne C, Hentic O, Hammel P, Muller N, Ponsot P, Levy P, Ruszniewski P.

Eur J Gastroenterol Hepatol. 2017 Aug;29(8):904-908. doi: 10.1097/MEG.0000000000000901.

PMID:
28471829
20.

The Largest European Single-Center Experience: 300 Laparoscopic Pancreatic Resections.

Dokmak S, Ftériche FS, Aussilhou B, Lévy P, Ruszniewski P, Cros J, Vullierme MP, Khoy Ear L, Belghiti J, Sauvanet A.

J Am Coll Surg. 2017 Aug;225(2):226-234.e2. doi: 10.1016/j.jamcollsurg.2017.04.004. Epub 2017 Apr 13.

PMID:
28414116

Supplemental Content

Loading ...
Support Center